Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment

• Sponsor: Bayer (Industry)
• Overall Status: Completed
• CT.gov ID: NCT02696642
• Collaborator: (none)
• Enrollment: 54
• Locations: 8
• Arms: 4
• Actual Duration (Months): 40.1
• Patients Per Site: 6.8
• Patients Per Site Per Month: 0.2

Study Details

Study Description

Brief Summary

To characterize the safety, tolerability, pharmacokinetics and immunogenicity of anetumab ravtansine in subjects with advanced solid cancers and with different degrees of hepatic or renal impairment

Condition or Disease	Intervention/Treatment	Phase
Neoplasms	Drug: Anetumab ravtansine (BAY94-9343)	Phase 1

Study Design

• Study Type: Interventional
• Actual Enrollment: 54 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: An Open Label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Anetumab Ravtansine in Subjects With Mesothelin-expressing Advanced Solid Cancers and Different Stages of Concurrent Hepatic or Renal Impairment
• Actual Study Start Date: Apr 14, 2016
• Actual Primary Completion Date: Jul 31, 2018
• Actual Study Completion Date: Aug 19, 2019

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Control group Anetumab ravtansine was given at 6.5 mg/kg body weight (BW) as a 1 hour intravenous (IV) infusion once every 3 weeks (Q3W) for subjects with adequate hepatic and renal function.	Drug: Anetumab ravtansine (BAY94-9343); All subjects received anetumab ravtansine 6.5 mg/kg BW (body weight) once every three weeks
Experimental: mild HI group Anetumab ravtansine was given at 6.5 mg/kg BW as a 1 hour IV infusion Q3W for subjects with mild hepatic impairment (HI).	Drug: Anetumab ravtansine (BAY94-9343); All subjects received anetumab ravtansine 6.5 mg/kg BW (body weight) once every three weeks
Experimental: moderate HI group Anetumab ravtansine was given at 6.5 mg/kg BW as a 1 hour IV infusion Q3W for subjects with moderate hepatic impairment (HI).	Drug: Anetumab ravtansine (BAY94-9343); All subjects received anetumab ravtansine 6.5 mg/kg BW (body weight) once every three weeks
Experimental: moderate RI group Anetumab ravtansine was given at 6.5 mg/kg BW as a 1 hour IV infusion Q3W for subjects with moderate renal impairment (RI).	Drug: Anetumab ravtansine (BAY94-9343); All subjects received anetumab ravtansine 6.5 mg/kg BW (body weight) once every three weeks

Outcome Measures

Primary Outcome Measures

1. Number of subjects with treatment-emergent adverse events (TEAEs) and significant abnormalities in safety assessments related to anetumab ravtansine (BAY94-9343) in each of the 4 treatment groups [After the first application of the study drug up until the safety follow up visit, i.e., 30-35 days after the last dose of the study drug.]

2. AUC for antibody drug conjugate (ADC), total antibody (TA), derivative 4 of maytansine (DM4), and S methyl derivate of DM4 (DM4-Me) after single (first) dose administration of anetumab ravtansine (BAY94-9343) in Cycle 1 [From pre-dose until 504 hours post dose during cycle 1]

3. AUC(0-tlast) for ADC, TA, DM4 and DM4-Me after single (first) dose administration of anetumab ravtansine (BAY94-9343) in Cycle 1 [From pre-dose until 504 hours post dose during cycle 1]

4. Cmax for ADC, TA, DM4 and DM4-Me after single (first) dose administration of anetumab ravtansine (BAY94-9343) in Cycle 1 [From pre-dose until 504 hours post dose during cycle 1]

Secondary Outcome Measures

1. Cmax,md for ADC, TA, DM4 and DM4-Me in Cycle 3 [From pre-dose until 504 hours post dose during cycle 3]

2. AUC(0-tlast)md for ADC, TA, DM4 and DM4-Me in Cycle 3 [From pre-dose until 504 hours post dose during cycle 3]

3. Number of subjects with positive immunogenicity results for anti anetumab ravtansine (BAY94-9343) antibodies (anti drug antibody [ADA]) [From pre-dose on Day1 of Cycle 1 until the safety follow-up visit, i.e., 30-35 days after the last dose of the study drug]

4. Number of subjects with positive immunogenicity results for anetumab ravtansine (BAY94-9343) neutralizing antibody (NAB) [From pre-dose on Day1 of Cycle 1 until the safety follow-up visit, i.e., 30-35 days after the last dose of the study drug]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Male or female subjects aged ≥18 years

• Histologically or cytologically confirmed, locally advanced or metastatic solid cancers known to express mesothelin on the tumor cell surface (e.g. predominantly epithelial [>=50% tumor component] pleural or peritoneal mesothelioma, epithelial ovarian cancer [including the fallopian tube or primary peritoneal], adenocarcinoma of the pancreas, triple-negative adenocarcinoma of the breast, non-small-cell adenocarcinoma of the lung, endometrial cancer, serous uterine cancer, gastric cancer [including the gastro-esophageal junction], colon cancer, cholangiocarcinoma, thymic carcinoma, etc.). Subjects with resected primary cancers who have documented metastases or local recurrence are eligible.

• Subjects must have no standard therapy available, or have actively refused standard therapy

• Subjects must meet the criteria for one of the 4 treatment groups:

• Group A: Adequate hepatic and renal function (controls)

• Group B: Mild hepatic impairment, i.e. Grade A according to the Child-Pugh Classification (total score of 5 or 6) and adequate renal function

• Group C: Moderate hepatic impairment, i.e. Grade B according to the Child-Pugh Classification (total score of 7, 8 or 9) and adequate renal function

• Group D: Moderate renal impairment, i.e. eGFR (estimated glomerular filtration rate) <60 and ≥30 mL/min per 1.73 m*2 and hepatic function better than, or equal to mild impairment according to the Child-Pugh Classification (total score ≤6)

• Adequate bone marrow function

• Life expectancy of at least 12 weeks

• ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1 (control and mild hepatic impairment groups), or 0-2 (moderate hepatic impairment and moderate renal impairment groups)

Exclusion Criteria:

• Subjects who have a previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study, except cervical carcinoma in situ, treated basal cell carcinoma, superficial noninvasive bladder tumors or any previous cancer curatively treated >3 years before the start of anetumab ravtansine

• Subjects who have new or progressive brain or meningeal or spinal metastases

• Subjects who have Gilbert's syndrome or other benign congenital hyperbilirubinemia are not eligible for the mild or moderate hepatic impairment or moderate renal impairment groups.

• Subjects who have a history or current evidence of bleeding disorder, i.e. any hemorrhage/bleeding event of CTCAE (Common Terminology Criteria for Adverse Events) Grade ≥2 bleeding within 4 weeks before the start of anetumab ravtansine

• Subjects who have a history or current evidence of uncontrolled cardiovascular disease or hypertension.

• Fridericia-corrected QT interval (QTcF) >480 ms, heart rate ≥100 beats per minute (bpm) or ≤45 bpm, LVEF (left ventricular ejection fraction) <50%

• Subjects with corneal epitheliopathy or any eye disorder that may predispose the subjects to drug-induced corneal epitheliopathy or may interfere with diagnosis of treatment-emergent corneal epitheliopathy at the investigator's discretion in consultation with an ophthalmologist.

• Subjects who have received systemic anticancer therapy (except pemetrexed, cisplatin, carboplatin and topical or intracavitary treatments with negligible absorption in systemic circulation ) within 4 weeks before the start of anetumab ravtansine, or within 5 half-lives of the anticancer agent before the start of anetumab ravtansine, whichever is longer. Mitomycin C or nitrosoureas must be excluded within 6 weeks before the start of anetumab ravtansine.

• Subjects who have received radiotherapy within 4 weeks before the start of anetumab ravtansine

• Use of drugs that, in the opinion of the investigator, have a strong potential for renal or hepatic toxicity within 2 weeks before the start of anetumab ravtansine until the EoT visit.

• Use of strong cytochrome P450 3A4 (CYP3A4) inhibitors or strong CYP3A4 inducers within 2 weeks before the start of anetumab ravtansine until the EoT visit

• Women who are pregnant or breast-feeding

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1		Caen		France	14073
2		Dijon		France	21079
3		Lille Cedex		France	59020
4		Lyon Cedex		France	69008
5		Marseille Cedex 5		France	13385
6		Saint Herblain		France	44805
7		Toulouse Cedex 9		France	31059
8		Chisinau		Moldova, Republic of	2025

Sponsors and Collaborators

• Bayer

Investigators

• Study Director: Bayer Study Director, Bayer

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

• Click here to find information about studies related to Bayer Healthcare products conducted in Europe.
• Click here to find results for studies related to Bayer products

Publications

None provided.

• Responsible Party: Bayer
• ClinicalTrials.gov Identifier: NCT02696642
• Other Study ID Numbers: 18327; 2015-003897-33
• First Posted: Mar 2, 2016
• Last Update Posted: Jul 9, 2021
• Last Verified: Jul 1, 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Bayer: mesothelin-expressing advanced solid cancers
• Additional relevant MeSH terms: Renal Insufficiency; Maytansine

Study Results

No Results Posted as of Jul 9, 2021